Meta AnalysisID 3930
钾离子竞争性酸阻滞剂(P-CAB)治疗胃酸相关性疾病的有效性与安全性：一项系统评价与网状Meta分析
CRD42022369570
Is PCAB more effective than PPI or placebo in treating and relieving symptoms of gastric acid-related diseases? Is PCAB safer for gastric acid-related diseases than PPI or placebo?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3930
- Evidence Id
- 12488
- Core Evidence Id
- 12488
- Source Meta Analysis Id
- 3889
- Herb2 Meta Analysis Id
- HBMA003889
- Crd Id
- CRD42022369570
- Title
- The efficacy and safety of potassium-competitive acid blockers (P-CAB) in gastric acid-related disease: a systematic review and network meta-analysis.
- Review Question
- Is PCAB more effective than PPI or placebo in treating and relieving symptoms of gastric acid-related diseases? Is PCAB safer for gastric acid-related diseases than PPI or placebo?
- Study Type Included
- We will only include RCT studies to assess the beneficial effects of the treatments.
- Condition Being Studied
- PCABs, a reversible H+-K+ ATPase inhibitor, have a faster and longer-lasting acid suppressive effect, which is not affected by diet and genes polymorphisms. In recent years, there have been many articles presenting the RCT results. Furthermore, non-randomized studies were included in previous meta-analyses, prone to biases and heterogeneity, among other limitations. Therefore, the current systematic review and meta-analysis included only robust randomized clinical trials (RCTs) of all studied PCABs. We will update the RCT study result of the latest regimen and assess the efficacy (superiority or non-inferiority) and safety of PCAB compared to PPIs or placebo in treating gastric acid-related diseases.
- Participant
- Patients with gastric acid-related diseases. Gastric acid-related diseases to be studied in this review included: erosive esophagitis, gastric and duodenal ulcers and gastroesophageal reflux disease (GERD).
- Animal
- Human Disease Modelled
- Intervention
- Potassium competitive acid blocker included: Vonoprazan, Soraprazan, Revaprazan, Tegoprazan, Keverprazan and Linaprazan.
- Comparator Control
- Proton pump inhibitor and placebo
- Main Outcome
- Upper GI endoscopic measurement of the erosive esophagitis healing rate (proportion) Upper GI endoscopy measurement of the ulcers healing rate (proportion) The eradication rate of Helicobacter pylori as assessed by urea breath test, Improvement in GI symptoms Measures of effect The pooled risk ratio (RR) was evaluated for the efficacy outcome
- Outcome Measure
- Additional Outcome
- treatment-emergent adverse events (TEAEs) as the safety outcome. Measures of effect Incidence and Risk Ratio
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Gastric Acid; Humans; Network Meta-Analysis; Potassium; Proton Pump Inhibitors; Pyrroles
- Contact
- Mengling Ouyang [email protected]
- Organisational Affiliation
- Huazhong University of Science and Technology
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-10-23
- Registration Date
- 2022-11-03
- Anticipated Start Date
- 2022-10-22
- Anticipated Completion Date
- 2023-02-28
- Title Cn
- 钾离子竞争性酸阻滞剂(P-CAB)治疗胃酸相关性疾病的有效性与安全性：一项系统评价与网状Meta分析
- Title En
- The efficacy and safety of potassium-competitive acid blockers (P-CAB) in gastric acid-related disease: a systematic review and network meta-analysis.
- Bilingual Status
- complete